Equity Overview
Price & Market Data
Price: $8.75
Daily Change: +$1.17 / 13.37%
Daily Range: $7.59 - $8.88
Market Cap: $1,422,096,512
Daily Volume: 17,691,723
Performance Metrics
1 Week: 32.03%
1 Month: 24.72%
3 Months: 47.56%
6 Months: 2.09%
1 Year: -22.85%
YTD: 9.20%
Company Details
Employees: 952
Sector: Health technology
Industry: Biotechnology
Country:
Details
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.